Skip to main content
. Author manuscript; available in PMC: 2016 Jun 2.
Published in final edited form as: Nat Rev Drug Discov. 2016 Jan 29;15(3):173–183. doi: 10.1038/nrd.2015.10

Figure 3.

Figure 3

The three integrins α4β1, α4β7 and αEβ7 targeted by therapeutic α4 and β7 antibodies. α4 (blue) and thus α4β1 and α4β7 are targeted by natalizumab. β7 (purple) and thus α4β7 and αEβ7 are targeted by etrolizumab. Vedalizumab and AMG-181 recognize an epitope formed by both α4 and β7 and thus is monospecific. The αE subunit (orange) contains an I domain (I). Main ligands for each integrin noted above. PML: progressive multifocal leukoencephalopathy.